Related Experiment Videos
Patent ductus arteriosus treated with ligation or indomethacin: a follow-up study
Insights
This study compared indomethacin treatment versus surgical ligation for patent ductus arteriosus (PDA) in infants. Results show no significant differences in long-term health outcomes between the two PDA closure methods.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Surgical Innovation
Background:
- Patent ductus arteriosus (PDA) is a common congenital heart condition in premature infants.
- PDA closure is crucial to prevent complications like respiratory distress and necrotizing enterocolitis.
- Pharmacologic closure with indomethacin and surgical ligation are primary treatment options.
Purpose of the Study:
- To compare the long-term outcomes of indomethacin treatment versus surgical ligation for PDA closure in infants.
- To assess somatic growth, neurologic function, and organ-specific development post-intervention.
Main Methods:
- Prospective assessment of 52 infants with PDA requiring closure.
- Randomized comparison of 26 infants receiving indomethacin and 26 undergoing surgical ligation.
- Longitudinal follow-up evaluating somatic, neurologic, psychomotor, mental, renal, ophthalmologic, and audiologic functions.
Main Results:
- No selective morbidity was attributed to indomethacin closure compared to surgical treatment.
- Longitudinal follow-up in 21 infants per group revealed comparable outcomes across assessed domains.
- Both PDA closure methods demonstrated similar safety and efficacy profiles in the long term.
Conclusions:
- Indomethacin is a safe and effective alternative to surgical ligation for PDA closure in infants.
- Long-term health outcomes are not significantly different between pharmacologic and surgical PDA treatment.
- This study supports the use of indomethacin as a primary treatment modality for PDA.
Abstract:
The course and complications of fifty-two infants with patent ductus arteriosus requiring closure were assessed prospectively. Twenty-six infants with a PDA received indomethacin for pharmacologic closure of the PDA, and 26 underwent ligation. The current study analyzes and compares the longitudinal follow-up with respect to somatic growth, neurologic function, psychomotor and mental development, and renal, ophthalmologic, and audiologic function in 21 infants in each group who entered the follow-up. No selective morbidity was attributable to PDA closure with indomethacin when compared to surgically treated infants.